Celon Pharma (LTS:0RKX) Total Stockholders Equity: zł528.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKX Celon Pharma SA LTS:0RKX
19 GF Score
Price zł22.50
! 4 Warning Signs
View Full Analysis

What is Celon Pharma Total Stockholders Equity?

Celon Pharma LTS:0RKX 19 Total Stockholders Equity is zł528.8 Mil as of Mar. 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Celon Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was zł528.8 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Celon Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was zł9.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Celon Pharma's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.10.

Celon Pharma  (LTS:0RKX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Celon Pharma's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(528.784-0)/53.857
=9.82

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Celon Pharma's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(20.822 + 32.855) / 528.784
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Total Stockholders Equity Related Terms

Celon Pharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Total Stockholders Equity Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 554.00 479.65 445.56 445.21 363.25

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 419.53 385.11 389.19 363.25 528.78
LTS:0RKX
19GF Score
Celon Pharma SA LTS:0RKX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of zł528.8 Mil mean?
Celon Pharma (LTS:0RKX) has a Total Stockholders Equity of zł528.8 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Celon Pharma and its competitors.
Is Celon Pharma's Total Stockholders Equity too high?
Celon Pharma's current Total Stockholders Equity is zł528.8 Mil. Overall, Celon Pharma has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Total Stockholders Equity compare to ZTS and UTHR?
Celon Pharma's Total Stockholders Equity of zł528.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Celon Pharma and its competitors. Celon Pharma's current Total Stockholders Equity is zł528.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Total Stockholders Equity of zł528.8 Mil. The current Total Stockholders Equity is zł528.8 Mil. Celon Pharma's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Total Stockholders Equity is zł528.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
19GF Score

Get the complete analysis for LTS:0RKX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price